|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From Brown University School of Medicine (Dr. Levy), Worcester, MA; University of Colorado Health Sciences Center (Dr. Abraham), Boulder, CO; Ortho Biotech Products (Dr. Zilberberg), L.P., Bridgewater, NJ; and Duke University Medical Center (Dr. MacIntyre), Durham, NC.
Correspondence to: Mitchell M. Levy, MD, FCCP, Professor of Medicine, Brown University School of Medicine, Division of Pulmonary and Critical Care Medicine, Rhode Island Hospital, 593 Eddy St, Main 7, Providence, RI, 02903; e-mail: mitchell_levy{at}brown.edu
| Abstract |
|---|
|
|
|---|
Design: Retrospective subgroup analysis from the prospective, multicenter, observational CRIT study.
Setting: Two hundred eighty-four medical, surgical, or medical/surgical ICUs.
Patients: Critically ill adults.
Main results: Of the 4,892 patients enrolled in the CRIT study, 60% were receiving MV on ICU admission or within 48 h after admission for a median of 4 days. Patients receiving MV had higher baseline APACHE (acute physiology and chronic health evaluation) II scores than patients not receiving MV (22.8 ± 7.8 and 14.9 ± 6.4, respectively [mean ± SD]; p < 0.0001). Despite similar baseline hemoglobin levels (11.0 ± 2.3 g/dL and 10.9 ± 2.5 g/dL, p = 0.17), more patients receiving MV underwent transfusions (49% vs 33%, p < 0.0001), and they received significantly more RBCs than patients not receiving MV (p < 0.0001). The principal reason for transfusion in both groups was low hemoglobin level (78.4% and 84.6%, respectively); however, patients receiving MV had higher pretransfusion hemoglobin levels (8.7 ± 1.7 g/dL) than patients not receiving MV (8.2 ± 1.7 g/dL, p < 0.0001). Notably, 40.1% of all transfusions in patients receiving MV were administered after day 3 of the ICU stay, compared to 21.2% in patients not receiving MV (p < 0.0001), and a higher percentage of patients receiving MV remaining in the ICU after day 3 underwent transfusions (33.4% vs 18.3%, p < 0.0001). Mortality was higher (17.2% vs 4.5%, p < 0.0001) and mean hospital (15 days vs 10 days, p < 0.0001) and ICU stays (9 days vs 4 days, p < 0.0001) were longer in the subgroup receiving MV.
Conclusions: Mechanical ventilation appears to be an easily identifiable early marker for allogeneic blood exposure risk in ICU patients. While the longer ICU stays account for much of this risk, patients receiving MV also appear to undergo transfusions at higher hemoglobin thresholds than patients not receiving MV, at least early in the ICU stay. Justification of this relatively liberal transfusion practice in patients receiving MV will require further study.
Key Words: anemia blood transfusions critical care hemoglobin length of stay mechanical ventilation severity of illness transfusion triggers
| Introduction |
|---|
|
|
|---|
Hébert and colleagues7 demonstrated that allogeneic transfusions did not improve outcomes in selected critically ill patients when administered at a liberal hemoglobin threshold (10 g/dL), compared to a more conservative hemoglobin threshold (7 g/dL). Liberal transfusion practices in the critically ill are also of concern because of mounting evidence that administration of blood in the ICU setting is associated with an increased incidence of nosocomial infections,89101112 multiple organ failure,13 and higher mortality rates.514 Of note, nearly one third of the critically ill patients in the retrospective study by Corwin and colleagues6 received transfusions for no clinically apparent reason.
A recent, large, international, prospective cohort study15 reported that approximately one third of all patients admitted to an ICU require mechanical ventilation (MV) at some point during their stay. This number approaches 70 to 85% in some published randomized, controlled trials71617 of ICU patients. It is well accepted that patients receiving MV are generally sicker and, as a result, tend to exhibit poorer outcomes, including prolonged ICU stays.181920 These patients, therefore, are likely to consume relatively large volumes of blood and represent a population whose transfusion characteristics are of considerable interest.
The US-based CRIT study4 was a prospective, multicenter, observational evaluation of anemia and transfusion practices in 4,892 patients from 284 ICUs. Within this broad data set, 60% of patients required MV within 48 h after ICU admission. This retrospective analysis of data collected during the CRIT study4 was performed to quantify and compare patterns of transfusions and blood usage in patients receiving MV and in patients not receiving MV. To understand better whether the propensity to remain in the ICU for a prolonged time period exposes patients to more blood transfusions, both the volume and timing of blood transfusions in the MV and non-MV cohorts of the CRIT population were examined. Differences in outcomes, namely, the ICU and hospital length of stay (LOS) and mortality, were also evaluated in these patient subsets.
| Materials and Methods |
|---|
|
|
|---|
18 years, anticipated ICU stay > 48 h, and informed consent. Exclusion criteria were as follows: admission to a pediatric, cardiothoracic, cardiac, neurologic, or burn ICU; renal failure on dialysis; patients prohibited from receiving RBC transfusions; and patients involved in other transfusion research protocols. Patients were followed up for 30 days, or until hospital discharge or death, whichever occurred sooner. The study protocol was approved by the institutional review board of each participating institution. Subsets of this population have since been used to describe transfusion practices in trauma patients21 and to explore the relationship of ventilator-associated pneumonia to RBC transfusions.22
Subjects and End Points
For the current analysis, MV patients were defined as those who were intubated on admission to the ICU or within 48 h of ICU admission. Because patients requiring new-onset MV late in their ICU course may represent a unique cohort, with ICU-related complications that likely influenced the process of care and outcomes, patients who were intubated later (> 48 h after ICU admission) were not included. Patients whose MV status was unknown were also excluded.
The primary purpose of the present analysis was to examine and quantify transfusion practices in the MV population of the CRIT study4 and compare them to practices in the population of non-MV patients. The hypothesisthat increased illness severity and propensity to remain in the ICU for a prolonged period of time put MV patients at an increased risk of receiving allogeneic bloodwas assessed by examining the percentage of patients receiving transfusions with packed RBCs during their ICU stay, the total volume of RBCs transfused to each subgroup, and per-patient numbers of RBC units transfused. Additionally, pretransfusion hemoglobin levels, reasons for transfusion, as well as the timing of RBC transfusions were analyzed, the latter to quantify the incidence of late (eg, later than ICU day 3) transfusions.
Statistical Analysis
Descriptive analyses of MV and non-MV populations and comparisons of transfusion requirements and outcomes between these groups were performed. SAS PROC MEANS procedure (SAS Institute; Cary, NC) was used to analyze means, SDs, and medians of continuous variables. Means are represented as ± SD, and medians are reported with their interquartile ranges (25th and 75th). A Student t test was used to detect significant differences between the mean values of two continuous variables. The nonparametric Brown-Mood test was used to compare differences between median values. SAS PROC FREQ procedure (SAS Institute) was used to tabulate frequencies of categorical variables, and
2 tests were used to detect significant differences between them; p < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
|
|
On a RBC unit per-patient basis, the difference in RBC units transfused in MV and non-MV patients was apparent in the early period (3.8 ± 4.1 U vs 3.1 ± 2.3 U, respectively; p < 0.0001), but this difference disappeared in the late ICU period (4.0 ± 3.6 U vs 3.9 ± 6.5 U, p = 0.9). The pretransfusion hemoglobin levels recorded as a function of the number of days spent in the ICU are shown in Figure 3 . The mean pretransfusion hemoglobin levels were significantly higher in MV patients in the first 3 days of the ICU stay (p < 0.0001), but thereafter showed no difference. This difference appears to fade because pretransfusion hemoglobin levels increase in non-MV patients as they spend more time in the ICU.
|
|
| Discussion |
|---|
|
|
|---|
Two prospective observational studies,45 one of which provides the study population for this subset analysis,4 documented that transfusions continue to be administered quite liberally in the ICU setting. This occurs despite mounting evidence about transfusion risks,8913 and despite data from Hébert et al7 that a restrictive transfusion policy (hemoglobin, 7 g/dL) produces outcomes similar to that of a liberal policy (hemoglobin, 10 g/dL) in selected critically ill patients.
The MV patients in this study had poorer outcomes than the non-MV patients. As may have been predicted from the severity of illness scores in the MV cohort, mortality, ICU LOS, and hospital LOS were higher than in the non-MV cohort. Because it is not valid to draw any causal inferences from an observational study, these data have not been analyzed with respect to allogeneic blood exposure and outcomes, and no implication of cause and effect is intended. Conversely, because of the close relationship observed between LOS and MV in the present data set, it is difficult to assess whether the higher amounts of RBC units transfused are due to prolonged LOS or MV alone. Future studies are warranted to further examine the relationships between transfusions and outcomes in MV patients.
Transfusion practices in critically ill MV patients are of interest for several reasons, not the least of which relates to the large amount of blood that this population consumes. A large proportion of ICU patients are intubated and placed on MV during their ICU stay; 60% in the present analysis were intubated within 48 h after ICU admission. While it may seem obvious, MV patients are generally sicker, their ICU stays are longer and, as a result, are a population likely to be transfused. Because these patients receive a significant number of RBC transfusions after ICU day 3, the MV population represents one in which a carefully constructed transfusion management strategy would benefit blood conservation efforts.
The present observations clearly indicate that clinicians transfuse MV patients, a priori, at higher hemoglobin levels (8.7 g/dL) than the non-MV patients (8.2 g/dL), at least early in the ICU course (Fig 3). Although the stated reason for most (80.2%) of the transfusions administered overall was low hemoglobin, these data also show that low hemoglobin has a statistically and clinically different meaning in MV and non-MV patients (8.4 ± 1.4 g/dL vs 8.0 ± 1.6 g/dL, respectively; p < 0.0001).
The clinical reasoning behind this difference in transfusion trigger between MV and non-MV patients is not obvious, since there is little existing evidence that hemoglobin should be corrected more aggressively in MV patients. It is noteworthy that multiple clinical trials272829 of liberation from MV have utilized hemoglobin levels of 8 g/dL or 10 g/dL as an enrollment criterion, perhaps representing a tacit assumption that there is a hemoglobin threshold necessary for successful extubation. Several studies3031 lend some support to this practice, including one by Khamiees et al,32 in which medical and cardiac ICU patients with hemoglobin levels
10 g/dL were more than five times as likely to have extubation failure as patients with hemoglobin levels > 10 g/dL. In contrast to the limited data suggesting that higher hemoglobin provides an advantage when weaning patients from MV, analysis of the MV subset from the Transfusion Practices in Critical Care study17 found no difference between the liberal and restrictive transfusion groups with respect to the duration of MV or the number of ventilator-free days. However, the Transfusion Practices in Critical Care study17 was neither designed nor powered to demonstrate MV outcome differences. Given the paucity of published data on the topic, the question of whether a higher hemoglobin is beneficial in MV patients remains unanswered and needs to be rigorously investigated in a prospective study.
The significant transfusion requirement in the MV population after ICU day 3 (40% of all blood administered to this group) is another pertinent observation arising from the present analysis. Although the number of RBC units transfused per patient in this late period was similar in both the MV and non-MV groups, the proportion of total blood administered to MV patients after ICU day 3 was higher (40% vs 21%). The MV patients were more than twice as likely to remain in the ICU past day 3 (73.8% MV vs 35.8% non-MV, p < 0.0001), and this longer ICU stay explains why such a large volume of blood is administered late to the MV population. Patients receiving ventilation received more than six times more blood than non-MV patients in this period (2,837 U vs 460 U, p < 0.0001), despite the fact that MV patients had shorter survival durations. MV is apparently an easily identifiable, early marker for predicting longer lengths of ICU stay and, hence, transfusion risk in the ICU. The observation that non-MV patients who continue to stay long in the ICU are transfused at higher hemoglobin levels lends support to the notion that LOS is an important factor in the decision to transfuse. Furthermore, the observation that the transfusion "trigger" increases over time in the ICU may reflect an attitude among clinicians that higher hemoglobin levels are beneficial with increasing severity of illness, despite a lack of data to support this clinical practice.
In summary, MV patients consume a significant amount of allogeneic blood while in the ICU, and blood is administered to these patients at a relatively high pretransfusion hemoglobin level. A large proportion of blood is administered late in the ICU course. Given the potential for untoward consequences of blood administration and the scarcity of the resource, it is appropriate to regularly evaluate blood utilization patterns in the MV critically ill population. Additional studies are also needed to address the potential beneficial effects of higher hemoglobin on outcomes in MV patients, whether achieved through transfusion or through strategies that minimize allogeneic blood exposure.
| Acknowledgements |
|---|
| Footnotes |
|---|
This work was presented, in part, at the Annual Meeting of the American Thoracic Society in Seattle, WA 2003.
This study was sponsored by Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ.
Received for publication February 9, 2004. Accepted for publication August 24, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. E. Craven Preventing ventilator-associated pneumonia in adults: sowing seeds of change. Chest, July 1, 2006; 130(1): 251 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Shorr and M. H. Kollef Ventilator-Associated Pneumonia: Insights From Recent Clinical Trials Chest, November 1, 2005; 128(5_suppl_2): 583S - 591S. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |